SAB BIO(SABSW)
MIAMI BEACH, FLBiotechnology
Focus: SAB BIO is a public biotech company developing a platform for fully human, polyclonal antibodies with initial focus on oncology. The company is early-stage with minimal revenue and significant R&D investment.
Profile data last refreshed 16h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
4-2 this month
Stable — net -2 jobs in 30d
2 added, 4 removed. Backfill posture.
Should You Work at SAB BIO?
AI assessmentSAB BIO offers high-risk/high-reward exposure to novel antibody platform technology, but severe cash constraints and lack of clinical validation make this suitable only for risk-tolerant candidates seeking early-stage impact.
Why Work Here
- Platform technology with potential for broad application across therapeutic areas beyond oncology
- Recent $175M funding commitment and 2027 trial timeline signal investor confidence and near-term catalysts
Data completeness
4/9 — Basic
Company HealthStrong
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$1M
Help build intelligence for SAB BIO
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.